The FDA has approved Eloctate, a new prophylactic treatment for children and adults with hemophilia A. The infusion is long-acting and will decrease the number of doses required, with an infusion needed every 3 to 5 days (rather than three times weekly or every other day).
Eloctate consists of the coagulation factor VIII molecule linked to a protein fragment (Fc), which makes the therapy last longer in the patient’s blood.
In a clinical trial of some 160 males aged 12 and older with severe hemophilia, Eloctate effectively treated, reduced, and prevented bleeding episodes. Additionally, it was effective in controlling perioperative bleeding.